Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

NCT02166346 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Transverse Myelitis
Neuromyelitis Optica
Idiopathic Transverse Myelitis
Myelitis NOS

Interventions

DRUG: Dalfampridine
DRUG: Placebo

Sponsor

Johns Hopkins University

Collaborators

[object Object]